Eyeworld Daily News

©2013 Novartis 2/13 NPF12014JAD References: 1. Ke T-L, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular infl ammation, II: In vitro bioactivation and permeation of external ocular barriers. Infl ammation. 2000;24(4):371-384. 2. Data on fi le. 3. ILEVRO ™ Suspension package insert. ONCE-DAILY POST-OP Designed to put potency precisely where you need it 1,2 NEW ILEVRO ™ Suspension One drop should be applied once daily beginning 1 day prior to surgery through 14 days post-surgery, with an additional drop administered 30 to 120 minutes prior to surgery 3 Use of ILEVRO™ Suspension more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk and severity of corneal adverse events 3 INDICATIONS AND USAGE ILEVRO ™ Suspension is a nonsteroidal, anti-in ammatory prodrug indicated for the treatment of pain and in ammation associated with cataract surgery. Dosage and Administration One drop of ILEVRO ™ Suspension should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the rst 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery. IMPORTANT SAFETY INFORMATION Contraindications ILEVRO ™ Suspension is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other NSAIDs. Warnings and Precautions t*ODSFBTFE#MFFEJOH5JNFo8JUITPNFOPOTUFSPJEBMBOUJJOýBNNBUPSZ drugs including ILEVRO ™ Suspension there exists the potential for increased bleeding time. Ocularly applied nonsteroidal anti-in ammatory drugs may cause increased bleeding of ocular tissues (including hyphema) in conjunction with ocular surgery. t%FMBZFE)FBMJOHo5PQJDBMOPOTUFSPJEBMBOUJJOýBNNBUPSZESVHT /4"*%T including ILEVRO ™ Suspension may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. t$PSOFBM&GGFDUTo6TFPGUPQJDBM/4"*%TNBZSFTVMUJOLFSBUJUJT*OTPNF patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. 5IFTFFWFOUTNBZCFTJHIUUISFBUFOJOH1BUJFOUTXJUIFWJEFODFPGDPSOFBM epithelial breakdown should immediately discontinue use. 1BUJFOUTXJUIDPNQMJDBUFEPDVMBSTVSHFSJFTDPSOFBMEFOFSWBUJPODPSOFBM epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which NBZCFDPNFTJHIUUISFBUFOJOH5PQJDBM/4"*%TTIPVMECFVTFEXJUI caution in these patients. 6TFNPSFUIBOEBZQSJPSUPTVSHFSZPSVTFCFZPOEEBZTQPTUTVSHFSZ may increase patient risk and severity of corneal adverse events. t$POUBDU-FOT8FBSo*-&730 ™ Suspension should not be administered while using contact lenses. Adverse Reactions 5IFNPTUGSFRVFOUMZSFQPSUFEPDVMBSBEWFSTFSFBDUJPOTGPMMPXJOHDBUBSBDU surgery occurring in approximately 5 to 10% of patients were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation. For additional information about ILEVRO ™ Suspension, please refer to the brief summary of prescribing information on adjacent page.

• Cover